Holdings
Fidelity Advisor Biotechnology Fund
As of Jul 31, 2026, Fidelity Advisor Biotechnology Fund reported 73 positions worth US$2.08B. Largest: Abbvie Inc., Gilead Sciences, Inc. and Spyre Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Abbvie Inc. | 1.29M | US$324M | −45,600 | Jul 31, 2026 |
| Gilead Sciences, Inc. | 964K | US$125M | +175K | Jul 31, 2026 |
| Spyre Therapeutics, Inc. | 857K | US$84.3M | +5,575 | Jul 31, 2026 |
| Alnylam Pharmaceuticals, Inc. | 387K | US$79.6M | +47,700 | Jul 31, 2026 |
| Dianthus Therapeutics, Inc. | 730K | US$78.1M | no change | Jul 31, 2026 |
| Cogent Biosciences, Inc. | 1.83M | US$71.4M | no change | Jul 31, 2026 |
| Oruka Therapeutics, Inc. | 737K | US$71.2M | no change | Jul 31, 2026 |
| Insmed Incorporated | 680K | US$67.1M | +191K | Jul 31, 2026 |
| Revolution Medicines, Inc. | 352K | US$66M | +52,700 | Jul 31, 2026 |
| Argenx Se | 77,200 | US$65.9M | no change | Jul 31, 2026 |